Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Luqun Wang, Wei Yang, Ting Niu, Yafei Wang, Rong Fu, Yuping Zhong, Kaiyang Ding, Kai Sun, Baijun Fang, Hong Liu, Wenbin Qian, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu

Blood (2024) 144 (Supplement 1): 7874.

https://doi.org/10.1182/blood-2024-201134

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6510.

https://doi.org/10.1182/blood-2024-201137

Published: 2024

Journal Articles

Efficacy and Safety of Carfilzomib-Based Regiments for the Treatment of Relapsed or Refractory Multiple Myeloma: Single-Center Real-Word Data

Weiwei Zhao, Juan Liu, Liyan Chen, Lianjie Wang, Yanming Xue, Yaoyao Tian, Yao Liu, Xiushuai Dong, Yuying Chang, Xi Chen, Liqian Yu, Xiaomin Zhang, Yinglan Jin, Yan Song, Biqing Han, Dandan Yao, Wei Wang

Blood (2024) 144 (Supplement 1): 7024.

https://doi.org/10.1182/blood-2024-204383

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6482.

https://doi.org/10.1182/blood-2024-201166

Published: 2024

Journal Articles

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Yuqin Song, Haiyan Yang, Youchao Jia, Lixia Sheng, Lijuan Deng, Xi Chen, Yongjing Tang, Xifang Liu, Sijun Liu, Min Wei, Feng Li

Blood (2024) 144 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2024-199342

Published: 2024

Journal Articles

Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China

Xi Chen, Haifeng Yu, Cong Li, Jieyu Xu, Tao Lei, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 7782.

https://doi.org/10.1182/blood-2024-207832

Published: 2024

Journal Articles

Novel Combination Regimen Brentuximab Vedotin-Bege Achieves Remarkable Efficacy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Xi Chen, Huilin Peng, Haifeng Yu, Cong Li, Tao Lei, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2024-207627

Published: 2024

Journal Articles

PK/PD Study of Zanubrutinib in Primary Chronic Lymphocytic Leukemia Patients

Zhenshu Xu, Ping Weng, Shujuan Xu, Yun Huang, Guangyao Guo, Zezhong Yu, Jie Lin, Liping Liu, Renyao Pan, Changgui Wang, Xi Chen, Yumenglin Bai

Blood (2024) 144 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2024-200091

Published: 2024

Journal Articles

Reduction of Radiotherapy Intensity after Achieving Complete Remission with Induction Chemotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma: A Prospective Study

Xi Chen, Li Xie, Ming Jiang, Liqun Zou

Blood (2024) 144 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2024-201965

Published: 2024

Journal Articles

Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma

Jeremiah C. Pfitzer, Razan Waliagha, Linda B. Baughn, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Shaji Kumar, Brian Van Ness, Gary Piazza, Amit K Mitra

Blood (2024) 144 (Supplement 1): 3263.

https://doi.org/10.1182/blood-2024-207683

Published: 2024

Journal Articles

Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Meijuan Wu, Xi Chen, Jialiang Lu, Weihao Zhuang, Chang He, Cong Li, Haifeng Yu, Tao Lei, Xiaowu Dong, Jianpeng Sheng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2024-203388

Published: 2024

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Lingling Wang, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2023-181063

Published: 2023

Journal Articles

A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6242.

https://doi.org/10.1182/blood-2023-184634

Published: 2023

Journal Articles

Real-World Analysis of Obinutuzumab-Based Immunochemotherapy in Follicular Lymphoma in Chinese Population

Xi Chen, Jieyu Xu, Haifeng Yu, Tao Lei, Cong Li, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6311.

https://doi.org/10.1182/blood-2023-189282

Published: 2023

Journal Articles

Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

Cong Li, Huixian HU, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6221.

https://doi.org/10.1182/blood-2023-184830

Published: 2023

Journal Articles

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Yusuke Isshiki, Patrizia Porazzi, Xi Chen, Matthew Teater, Ioannis Karagiannidis, Henna S. Nam, Ari M Melnick, Marco Ruella, Wendy BÃ©guelin

Blood (2023) 142 (Supplement 1): 432.

https://doi.org/10.1182/blood-2023-190610

Published: 2023

Journal Articles

PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Xi Chen, Yingying Chen, Tao Lei, Haifeng Yu, Cong Li, Yongwei Hong, Haiyan Yang

Blood (2023) 142 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2023-182685

Published: 2023

Journal Articles

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2023-184694

Published: 2023

Journal Articles

Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) Alone in Chinese Patients with Relapsed/Refractory Multiple Myeloma: Final Analysis of the Phase 3 Lepus Study

Weijun Fu, Xue Gai, Weiping Liu, Xi Chen, Canchan Cui, Jin Lu

Blood (2023) 142 (Supplement 1): 6719.

https://doi.org/10.1182/blood-2023-181025

Published: 2023

Journal Articles

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xinglu Zhou

Blood (2023) 142 (Supplement 1): 3139.

https://doi.org/10.1182/blood-2023-185241

Published: 2023

NARROW

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study

Efficacy and Safety of Carfilzomib-Based Regiments for the Treatment of Relapsed or Refractory Multiple Myeloma: Single-Center Real-Word Data

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China

Novel Combination Regimen Brentuximab Vedotin-Bege Achieves Remarkable Efficacy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

PK/PD Study of Zanubrutinib in Primary Chronic Lymphocytic Leukemia Patients

Reduction of Radiotherapy Intensity after Achieving Complete Remission with Induction Chemotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma: A Prospective Study

Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma

Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma

Real-World Analysis of Obinutuzumab-Based Immunochemotherapy in Follicular Lymphoma in Chinese Population

Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) Alone in Chinese Patients with Relapsed/Refractory Multiple Myeloma: Final Analysis of the Phase 3 Lepus Study

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only